Guardant Health (DE:5GH)
NASDAQ:5GH
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.66Last Year’s EPS
-0.7Same Quarter Last Year
Strong Buy
Based on 21 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strongly positive operational and commercial quarter: revenue growth was robust across Oncology, Biopharma & Data and Screening, Shield showed breakout traction with meaningful margin improvement, and product and data investments (InfinityAI, NovaSeq X transition, expanded FDA approvals and partnerships) support multi-year upside. Key near-term challenges include elevated operating expenses to fund growth, ongoing adjusted losses and free cash flow burn, and dependencies on reimbursement and third-party regulatory outcomes (MolDx reviews, drug approvals) that introduce timing and upside uncertainty. Overall, positives (accelerating revenue, volume, margin improvement, data/AI progress, and strengthened partnerships) materially outweigh the risks, though execution and reimbursement milestones remain important to sustain momentum.Company Guidance
Strong Top-Line Revenue Growth and Raised Guidance
Q1 revenue of $302 million, up 48% year-over-year; company surpassed $1 billion trailing 12-month revenue. Raised full-year 2026 revenue guidance to $1.30B–$1.32B (32%–34% growth).
Oncology Momentum — Volume and Revenue Expansion
Oncology revenue $205 million, up 36% YoY; oncology test volumes ~86,000, up 47% YoY. Guardant360 Liquid volumes +30% YoY; Guardant360 Tissue is the second-fastest growing product; Reveal volumes >100% YoY. Company expects oncology revenue growth of 28%–29% and oncology volume growth >35% for 2026.
Breakout Screening (Shield) Performance
Shield revenue $42 million vs $6 million in Q1 2025 with ~44,000 tests (prior ~9,000). Strong March momentum following nationwide Quest launch and DTC/HCP campaigns. Shield guidance increased to $186M–$198M for 2026, implying ~230k–245k Shield tests.
Material Improvement in Screening Economics
Screening non-GAAP gross margin improved from 18% (Q1 2025) to 56% (Q1 2026). Shield non-GAAP cost per test declined from $520 to $420 YoY; Medicare fee-for-service rate established at $1,495 (effective 2026–2027). Company expects Shield cost per test to fall to ~ $200 at scale (targeted for 2027).
Biopharma & Data Growth and Strategic Partnerships
Biopharma & Data revenue $53 million, up 17% YoY. Expanded CDx footprint with 26 approvals across U.S., Japan and Europe (recent approvals with Pfizer/Arvinas); multiyear agreement with Merck and collaboration with Nuvalent; InfinityAI-generated RWE contributed to a tumor-agnostic approval in Japan.
Improved Margins Driven by Sequencing Cost Reduction
Non-GAAP gross margin of 66% in Q1 2026 (vs 65% prior year), primarily due to NovaSeq X transition lowering Guardant360 Liquid sequencing cost per test by nearly $200 vs Q1 2025. Company expects FY non-GAAP gross margin of 64%–65%.
Data Treasury and AI Platform Progress
Data repository exceeds 1 million patient samples and 500,000 epigenetic profiles across >100 tumor types; InfinityAI powering 25 of 38 AACR abstracts and multiple Smart Apps; ongoing smart app pipeline and Reveal data submissions to MolDx.
Operational Strength and Cash Position
Adjusted EBITDA loss of $59 million (flat YoY). Free cash flow burn $71 million in Q1 (vs $67M prior year); excluding increased bonus impact, FCF burn decreased by ~$12 million YoY. Ended Q1 with ~ $1.2 billion in cash and investments and reiterated plan to reduce full-year 2026 FCF burn and achieve company-wide cash flow breakeven by end of 2027.
Commercial and Patient Engagement Catalysts
Nationwide Quest collaboration launched, EMR connectivity expanded (fast-tracked to >650,000 HCPs), DTC campaign including Patrick Dempsey generated >1 billion impressions, and Shield adherence >90%. FDA approved reduction of Shield kit from 4 blood tubes to 2, improving patient experience.
DE:5GH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:5GH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | €78.17 | €79.93 | +2.25% |
Feb 19, 2026 | €90.94 | €93.04 | +2.31% |
Oct 29, 2025 | €69.18 | €78.90 | +14.05% |
Jul 30, 2025 | €37.48 | €39.46 | +5.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Guardant Health (DE:5GH) report earnings?
Guardant Health (DE:5GH) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Guardant Health (DE:5GH) earnings time?
Guardant Health (DE:5GH) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Guardant Health stock?
The P/E ratio of Guardant Health is N/A.
What is DE:5GH EPS forecast?
DE:5GH EPS forecast for the fiscal quarter 2026 (Q2) is -0.66.